New drug combo aims to outsmart resistant leukemia

NCT ID NCT06399640

Recruiting now Disease control Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adults and look for the best dose and any signs of remission. Both drugs work by blocking proteins that help cancer cells survive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eltanexor and venetoclax
What this could lead to: If this works, it could offer a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so it is primarily testing safety and dosing. It may not lead to a proven treatment, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY MYELODYSPLASTIC SYNDROME RELAPSED MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Baptist Health Care Corporation
RECRUITING

Memphis, Tennessee, 38138, United States
Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.